No Data
No Data
Nuoweizan (688105.SH): A wholly-owned subsidiary has obtained two medical instrument registration certificates.
On August 7th, Gelunhui reported that Novozen (688105.SH) announced that its wholly-owned subsidiary, Nanjing Novozen Medical Technology Co., Ltd., recently received two Medical Instrument Registration Certificates issued by the National Medical Products Administration.
Nuoweizhan (688105.SH): Cumulative repurchase of 1.04% of its shares.
On August 2nd, Gelunhui reported that as of July 31, 2024, the company has repurchased 4,161,077 shares of the company's stock through the Shanghai Stock Exchange's centralized bidding trading system, accounting for 1.04% of the company's total share capital of 400,010,000 shares. The lowest price for the repurchase transactions was 18.80 yuan per share, the highest price was 28.65 yuan per share, and the total amount paid was 101,445,710.76 yuan RMB (excluding transaction fees).
Nanjing Vazyme Biotech's Unit Gets Approval to Sell Two Medical Devices in Europe
Novogene (688105.SH): Subsidiary's product obtains EU CE IVDR certification.
On July 16, Gelonhui reported that Nouveau Life Sciences (688105.SH) announced that some products of its wholly-owned subsidiary, Nanjing Nouveau Life Sciences Medical Technology Co., Ltd., have recently obtained EU CE IVDR certification and can be sold in EU countries and countries that recognize EU CE certification. The fully automatic medical PCR analysis system and matching sample preservation solution obtained by the company this time can be used with microfluidic chips (test kits) to control fluids through digital microfluidic chip technology, and complete nucleic acid extraction, amplification, and detection of the test sample in the microfluidic chip.
Private Companies Invested in Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) up 5.3% Last Week, Insiders Too Were Rewarded
Voluntary disclosure announcement of Noritz's 2024 interim performance forecast.
No Data